La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Paul J. Bedard And NotAutriche

List of bibliographic references

Number of relevant bibliographic references: 10.
Ident.Authors (with country if any)Title
001C85 Robert A. Hodgson [États-Unis] ; Paul J. Bedard [Canada] ; Geoffrey B. Varty [États-Unis] ; Tatiana M. Kazdoba [États-Unis] ; Therese Di Paolo [Canada] ; Michael E. Grzelak [États-Unis] ; Annamarie J. Pond [États-Unis] ; Abdallah Hadjtahar [Canada] ; Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; Aurelie Dare [Canada] ; Bernard R. Neustadt [États-Unis] ; Andrew W. Stamford [États-Unis] ; John C. Hunter [États-Unis]Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
002366 Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [États-Unis] ; Pershia Samadi [Canada] ; Paul J. Bedard [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Therese Di Paolo [Canada]Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys
002914 Carl Julien [Canada] ; Line Berthiaume [Canada] ; Abdallah Hadj-Tahar [Canada] ; Ali H. Rajput [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Pierre Julien [Canada] ; Frédéric Calon [Canada]Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys
002B30 Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada]Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
002F15 Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada]Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems
002F47 Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada]Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys
003103 Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment
003289 Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Daniel Levesque [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model
003332 ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada]Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys
003557 ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada]Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022